Umeclidinium

DEA Class; Rx

Common Brand Names; Incruse Ellipta

•  Anticholinergics, Respiratory

Severe hypersensitivity to milk proteins

Demonstrated hypersensitivity to umeclidinium or any of the excipients

• Nasopharyngitis (8%)
• Upper respiratory tract infection (5%)
• Cough (3%)
• Arthralgia (2%
• Toothache (1%)
• Pharyngitis (1%)
• Viral upper respiratory tract infection (1%)
• Tachycardia (1%)
• Atrial fibrillation

Anaphylactic reactions reported in patients with severe milk protein allergy after inhalation of other powder products containing lactose (see Contraindications)

Hypersensitivity reactions such as anaphylaxis, angioedema, pruritus, rash, and urticaria may occur; discontinue if reactions occur

Do not initiate in patients during rapidly deteriorating or potentially life-threatening episodes of COPD; not be used for the relief of acute symptoms (ie, as rescue inhaler) from acute episodes of bronchospasm

Paradoxical bronchospasm reported; discontinue and treat immediately with an inhaled, prompt-acting bronchodilator (eg, albuterol)

Worsening of narrow-angle glaucoma may occur

Worsening of urinary retention may occur; caution in patients with prostatic hyperplasia or bladder-neck obstruction

There are insufficient data on use in pregnant women to inform a drug-associated risk

There is no information available on presence of drug in human milk, effects on breastfed child, or on milk production

Umeclidinium bromide

powder for inhalation

• 62.5mcg/actuation